No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
about
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesInflammatory process in Alzheimer's DiseaseThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.Omega-3 fatty acids and dementia.Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of agingAlzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.Presenilin/gamma-Secretase and Inflammation.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-betaAlzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.Brain imaging in the study of Alzheimer's diseaseIntracellular amyloid and the neuronal origin of Alzheimer neuritic plaquesThree midlife strategies to prevent cognitive impairment due to Alzheimer's disease.Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease.Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology.Extended results of the Alzheimer's disease anti-inflammatory prevention trial.Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.New pathway links γ-secretase to inflammation and memory while sparing notch.Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin.Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.NSAID Use and Incident Cognitive Impairment in a Population-based Cohort.Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors.Cross-sectional association between polyfluoroalkyl chemicals and cognitive limitation in the National Health and Nutrition Examination SurveyHigh serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patientsInteractions between APP secretases and inflammatory mediators.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort.Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.Imaging microglial activation during neuroinflammation and Alzheimer's disease.Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease.Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer's Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan.
P2860
Q24203739-B66B1FE2-16D9-4AE3-87ED-D4996287B7F6Q24235107-A8570A17-9FB4-43E1-8B59-BE94AB884012Q24236199-9F1C831D-CD97-4E95-BA01-30C5A7D1A7A6Q27500412-0AB3ECF2-B6D5-47E9-BCAE-E8E48167D53FQ30668465-73855A98-4DC4-4C21-87B1-ACFBE2D9EF3EQ33496256-51D4A183-83F4-4AF1-9969-B99ECE84B00AQ33588687-468F48A2-3864-4A28-A32D-5E2ABA9E71C4Q33602402-8842FFAB-1E92-4FAB-B6C3-80F1DDB907EEQ33706542-B4AFD720-517C-46D1-99ED-BD98F85599FDQ33773031-7A1312C3-92A4-4ABE-85EC-9814DD626160Q33810933-DDBDEEF6-7AE6-4D60-B412-0BC9C957C837Q33877897-FE6C1BA1-96B1-4DEB-AEE2-1B93A717CFA9Q33904501-9D05B9C7-AE3B-4A58-BE60-893CC46C850AQ33918695-C3A34E6B-0147-4F63-B4FE-9B5EB9663187Q33967781-D43C9234-3B4C-4992-A33B-D956B9B64773Q34009618-188FAE96-7DE5-4770-9C1E-5241FFFCF482Q34039983-D7576830-A2DF-4599-890C-734E3521B0CCQ34102331-8D7CC71A-3300-4B7D-9520-B4C574C4A9B0Q34266573-2CE8E29D-278B-4FEE-8E60-BC3F8894BCEDQ34536301-62787F7F-E3D3-4961-90BA-A33DFEEACB54Q35061264-E157B8F0-3444-45A0-8902-1C9FE6BC41DCQ35087578-89765D72-58D3-43A1-9141-381B30879C2DQ35146385-8EC2CEEE-C2D7-4474-897E-E3F24330AD80Q35523832-C2B8B7BE-E6A4-4043-8A69-CFEB58A9532FQ35743015-E19369ED-5154-48B2-8ABF-7CCDF045B272Q35806684-429D8708-AE35-46C4-9C6D-6EC8360AC280Q35913521-C4369052-B2E9-41A3-9A55-62316D515270Q36048230-5CF904FF-C6F2-47E9-B6D2-C8AB9751BDC5Q36348370-09B2A19D-7D31-4308-BBEB-966A52018A47Q36379542-24F4F358-0983-4206-971E-0EEB880EA32BQ36856193-22D5C195-6A6C-45FC-9165-1A0B0F878465Q37009902-427CC009-1025-43BF-87AE-5717501E70E8Q37195010-A35F41AE-D096-4DE8-A880-594C3F90CE8FQ37198579-461E95FD-E845-4937-B653-71CBC335CF05Q37213692-45F63730-5235-4935-A315-EBFF1D5CF852Q37219776-D9291C9A-E53B-419A-8DAF-B0882B528169Q37314262-C9DE8AEB-63A3-4D96-B16E-5B1E0FF2D3E5Q37340359-2B6221AD-A371-4701-B6F9-A4F1747A292DQ37364086-F0A93A1A-A952-44E2-8EA4-95CF50ACDEA8Q37404793-8FC67312-BFA9-408F-B602-389004E76534
P2860
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@ast
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@en
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@nl
type
label
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@ast
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@en
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@nl
prefLabel
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@ast
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@en
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@nl
P2093
P2860
P50
P3181
P1433
P1476
No advantage of A beta 42-lowe ...... a in six pooled cohort studies
@en
P2093
C A Szekely
J C S Breitner
K A Welsh-Bohmer
L H Kuller
P2860
P304
P3181
P356
10.1212/01.WNL.0000313933.17796.F6
P407
P577
2008-05-28T00:00:00Z